Advertisement

Molecular and Cellular Biochemistry

, Volume 355, Issue 1–2, pp 173–178 | Cite as

Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer

  • Vesna V. Dragutinović
  • Nevena V. Radonjić
  • Nataša D. Petronijević
  • Svetislav B. Tatić
  • Ivan B. Dimitrijević
  • Nebojša S. Radovanović
  • Zoran V. Krivokapić
Article

Abstract

Colorectal cancer is one of the leading causes of cancer related death in developed countries. One of the reasons is the absence of tumor specific diagnostic and prognostic markers. The aim of this study was to examine the correlation of matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) expressions in serum and clinicopathological features of the colorectal adenocarcinoma. Another aim was to examine expression of MMP-9 in the tissue of the colorectal carcinoma in MMP-9 serum positive patients. In addition, we tried to establish the correlation between preoperative levels of serum markers (CEA and CA 19-9) and presence of MMP-2 or MMP-9. The study was performed on 32 patients with colorectal adenocarcinoma who underwent surgery and 11 patients in a control group who were operated for benign diseases. The samples were analyzed by SDS-PAGE to determine the molecular mass and SDS-PAGE zymography to determine levels of MMP-2 and MMP-9. Expression of MMP-9 was determined immunohistochemically in the tissue of the colorectal carcinoma of MMP-9 serum positive patients. MMP-2 and MMP-9 levels were increased in the serum of the patients with colorectal cancer compared to the control group. There was significant correlation in MMPs levels among the patients with tumor stage I and II and the patients with tumor stage III and IV. Obtained results did not demonstrate correlation between levels of CEA, CA 19-9 and presence of MMP-2 or MMP-9. MMP-9 expression was positive in 85% of MMP-9 serum positive patients with colorectal carcinoma. The overexpression of MMP-2 and MMP-9 strongly suggests its association with colorectal adenocarcinoma. Detection of MMP-2 and MMP-9 in serum might be useful for identification of patients with higher risk for colorectal cancer recurrence.

Keywords

Matrix metalloproteinases Colorectal cancer CEA CA 19-9 Immunohistochemistry 

Notes

Acknowledgment

We thank the Ministry of Science of the Republic of Serbia (Project 41033) for financial support.

References

  1. 1.
    Wiggers T, Arends JW, Schutte B, Volovics L, Bosman FT (1988) A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer 61(2):386–395PubMedCrossRefGoogle Scholar
  2. 2.
    Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253(5015):49–53PubMedCrossRefGoogle Scholar
  3. 3.
    Liotta LA, Stetler-Stevenson WG (1993) Principles of molecular cell: biology of cancer: cancer metastasis. In: De Vita T, Hellman S, Rosenberg S (eds) Cancer, principles and practice of oncology. J.B. Lippincot Co., Philadelphia, pp 134–149Google Scholar
  4. 4.
    Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491–21494PubMedCrossRefGoogle Scholar
  5. 5.
    Zucker S, Lysik RM, Zarrabi MH, Moll U (1993) M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53:140–146PubMedGoogle Scholar
  6. 6.
    Hoikkala S, Paakko P, Soini Y, Makitaro R, Kinnula V, Turpeenniemi-Hujanen T (2005) Tissue MMP-2/TIMP-2-complex are better prognostic factors than serum MMP-2, MMP-9 or TIMP-1 in stage I-III lung carcinoma. Cancer Lett 236:125–132PubMedCrossRefGoogle Scholar
  7. 7.
    Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T (2005) Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 116:422–427PubMedCrossRefGoogle Scholar
  8. 8.
    Shen KH, Chi CW, Lo SS, Kao HL, Lui WY, Wu CW (2000) Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer. Anticancer Res 20:1307–1310PubMedGoogle Scholar
  9. 9.
    Hayasaka A, Suzuki N, Fujimoto N, Syousuke I, Etsuo F, Yoshiro K, Hiromitsu S (1996) Elevated plasma levels of matrix metalloproteinase-9 (92 kDa type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24:1058–1062PubMedCrossRefGoogle Scholar
  10. 10.
    Endo K, Maehara Y, Baba H, Yamamoto M, Tomisaki S, Watanabe A, Kakeji Y, Sugimachi K (1997) Elevated levels of serum and plasma metalloproteinases in patient with gastric cancer. Anticancer Res 17:2253–2255PubMedGoogle Scholar
  11. 11.
    Torii A, Kodera Y, Uesaka K, Kiarai T, Yasni K, Morimoto T, Yamamura Y, Kato T, Hayakawa T, Fujimoto N, Kito T (1997) Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg 84:133–136PubMedCrossRefGoogle Scholar
  12. 12.
    Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE (2005) Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activites. Clin Biochem 38(5):410–414PubMedCrossRefGoogle Scholar
  13. 13.
    Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE (2005) Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activites. Anal Biochem 344(1):147–149PubMedCrossRefGoogle Scholar
  14. 14.
    Gerlach RF, Demacq C, Jung K, Tanus-Santos JE (2007) Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-levels in serum versus plasma. Clin Biochem 40(1–2):119–123PubMedCrossRefGoogle Scholar
  15. 15.
    Manello F, Tanus-Santos JE, Meschiari CA, Tonti GA (2008) Differences in the both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices. Anal Biochem 374:56–63CrossRefGoogle Scholar
  16. 16.
    Dragutinović V, Izrael Živković L, Radovanović N (2009) Relation of matrix metalloproteinase-9 to different stages of tumors in serum of gastric cancer. Dig Dis Sci 54:1203–1207PubMedCrossRefGoogle Scholar
  17. 17.
    Mannello F (2008) Serum or plasma samples? the “Cinderella” role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 28(4):611–614PubMedCrossRefGoogle Scholar
  18. 18.
    Gerlach RF, Meschiari CA, Marcaccini AM, Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE (2009) Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions. Clin Chem Lab Med 47(7):888–891PubMedCrossRefGoogle Scholar
  19. 19.
    Goldstein MJ, Mitchell EP (2005) Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23(4):338–351PubMedGoogle Scholar
  20. 20.
    Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685PubMedCrossRefGoogle Scholar
  21. 21.
    Kleiner DE, Stetler-Stevenson WG (1994) Quantative zymography detection of picogram quantities of gelatinases. Anal Biochem 218:325–329PubMedCrossRefGoogle Scholar
  22. 22.
    Leeman MF, McKay JA, Murray GI (2002) Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer. J Clin Pathol 55(10):758–762PubMedCrossRefGoogle Scholar
  23. 23.
    Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI (2004) Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res 10(24):8229–8234PubMedCrossRefGoogle Scholar
  24. 24.
    Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT (2007) Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13(7):2054–2060PubMedCrossRefGoogle Scholar
  25. 25.
    Liotta LA, Stetler-Stevenson WG (1990) Metalloproteinases and cancer invasion. Semin Cancer Biol 1:99–106PubMedGoogle Scholar
  26. 26.
    Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270PubMedCrossRefGoogle Scholar
  27. 27.
    Stetler-Stevenson WG (1990) Type IV colagenases in tumor invasion and metastasis. Cancer Metastsis Rev 9:289–303CrossRefGoogle Scholar
  28. 28.
    Jadhav U, Chigurupati S, Lakka SS, Mohanam S (2004) Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells. Int J Oncol 25:1407–1414PubMedGoogle Scholar
  29. 29.
    Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 48:411–424PubMedCrossRefGoogle Scholar
  30. 30.
    Curran S, Murray GI (1999) Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189:300–308PubMedCrossRefGoogle Scholar
  31. 31.
    Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI (2004) Matrix metalloproteinase (MMP/TIMP) phenotype identifies poor prognosis colorectal cancer. Clin Cancer Res 10:8229–8234PubMedCrossRefGoogle Scholar
  32. 32.
    Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill JE (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2:461–462PubMedCrossRefGoogle Scholar
  33. 33.
    Cho YB, Lee WY, Song SY, Shin HJ, Yun SH, Chun HK (2007) Matrix metalloproteinase-9 activity is associated with poor prognosis in T3–T4 node-negative colorectal cancer. Hum Pathol 38:1603–1610PubMedCrossRefGoogle Scholar
  34. 34.
    Langenskiold M, Holmdahl L, Falk P, Ivarsson ML (2005) Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis 20:245–252PubMedCrossRefGoogle Scholar
  35. 35.
    Jeziorska M, Haboubi NY, Schofield PF, Ogata Y, Nagase H, Woolley DE (1994) Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma. Int J Colorectal Dis 9:141–148PubMedCrossRefGoogle Scholar
  36. 36.
    Herszényi L, Sipos F, Galamb O, Solymosi N, Hritz I, Miheller P, Berczi L, Molnár B, Tulassay Z (2008) Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. Pathol Oncol Res 14(1):31–37PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Vesna V. Dragutinović
    • 1
  • Nevena V. Radonjić
    • 2
  • Nataša D. Petronijević
    • 2
  • Svetislav B. Tatić
    • 3
  • Ivan B. Dimitrijević
    • 4
  • Nebojša S. Radovanović
    • 4
    • 5
  • Zoran V. Krivokapić
    • 4
    • 5
  1. 1.Institute of Medical Chemistry, School of MedicineUniversity of BelgradeBelgradeSerbia
  2. 2.Institute of Medical and Clinical Biochemistry, School of MedicineUniversity of BelgradeBelgradeSerbia
  3. 3.Institute of Pathology, School of MedicineUniversity of BelgradeBelgradeSerbia
  4. 4.Clinic for Digestive SurgeryFirst Surgical Clinic, Clinical Center of SerbiaBelgradeSerbia
  5. 5.School of MedicineUniversity of BelgradeBelgradeSerbia

Personalised recommendations